82-45-1Relevant articles and documents
Hydrogenation of 1-nitroanthraquinone to 1-aminoanthraquinone catalyzed by bimetallic cuptx nanoparticles
Yang, Chenchen,Wang, Aili,Yin, Hengbo
, p. 5906 - 5913 (2019)
Bimetallic CuPtx nanoparticles were prepared in ethanol solution by the wet chemical reduction method using Cu(NO3)2 and H2PtCl6 as starting materials, hydrazine hydrate as a reductant, and polyvinyl pyrrolidone as an organic modifier. The average particle sizes of Cu and Pt nanoparticles were 60 nm and 3 nm, respectively. The small-sized Pt nanoparticles were evenly anchored at the surfaces of large-sized Cu nanoparticles, forming Cu@Pt core-shell structured nanocomposites. In the bimetallic CuPtx nanoparticles, electron was transferred from platinum to copper species, which increased the selectivity of 1-aminoanthraquinone by suppressing the high hydrogenation activity of metallic platinum. The CuPt0.1 bimetallic nanoparticles exhibited higher catalytic activity for the hydrogenation of 1-nitroanthraquinone to 1-aminoanthraquinone than both monometallic Cu and Pt nanoparticles. Over the CuPt0.1 catalyst, the selectivity of 1-aminoanthraquinone was 99.3% at the 1-nitroanthraquinone conversion of 98.9%.
Copper-catalyzed one-pot relay synthesis of anthraquinone based pyrimidine derivative as a probe for antioxidant and antidiabetic activity
Ahmad, Zaheer,Arshad, Uzma,Parveen, Shagufta,Rafiq, Naila,Shafiq, Nusrat,Zarren, Gul
, (2020/12/17)
Synthetic compounds have modernized the globe due to its vast applicable fields. Anthraquinones, as well as pyrimidine derivatives, are used as essential pharmacophores in the field of medicine. Maintenance of a green disease-free environment by using these derivatives is being acknowledged in developed as well as developing countries of the world. Considering the use of active catalysts in the synthesis of anthraquinone based derivatives are the era of concern for researchers due to their distinctive properties. Owing to the remarkable activities of anthraquinone and pyrimidine derivative, we synthesize compounds having both functionalities with the utilization of novel synergically active copper catalysts. This study explores the application of synthesized compounds using fast, ecofriendly and cost-effective approaches.1H and 13C NMR, antioxidant, antidiabetic, molecular docking and QSAR studies were used for characterization and evaluation of newly synthesized anthraquinone based pyrimidine derivatives. The result of these techniques shows that our desired compounds were successfully synthesized and have potent applications. Among all synthesized compounds, G2 and G3 showed a remarkable antioxidant activity with IC50 of 15.09 and 21.88 μg/ml respectively. While the compound G2 and G4 showed a strong inhibitory antidiabetic activity with the IC50 value of 24.23 and 28.94 μg/ml respectively. Furthermore, molecular docking results for both of the proteins assist the experimental data and confirms the different interactions between binding domains and substituent moieties. SAR study also relates to the experimental facts by giving us positive results of synthesized compounds. According to the QSAR study, G4 and G2 emerged as the most stable and most reactive compound among other compounds respectively. While MEP shows moderate to good nucleophilic and electrophilic reactivity of all four compounds.
TARGETED BIFUNCTIONAL DEGRADERS
-
, (2021/04/17)
The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.
